Acurx Pharmaceuticals (ACXP, Financial) has announced a significant financial strategy by filing with the SEC for a $50 million mixed securities shelf offering. This move allows the company the flexibility to issue various types of securities, which could include common stock, preferred shares, or debt securities, at different times. This strategic filing is intended to provide Acurx with additional capital options to support its operations and potential growth initiatives.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Acurx Pharmaceuticals Inc (ACXP, Financial) is $5.70 with a high estimate of $8.29 and a low estimate of $1.50. The average target implies an upside of 1,039.50% from the current price of $0.50. More detailed estimate data can be found on the Acurx Pharmaceuticals Inc (ACXP) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Acurx Pharmaceuticals Inc's (ACXP, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
